We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $118K invested in XTL Biopharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

24% less capital invested

Capital invested by funds: $155K → $118K (-$37K)

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$34K
2
Morgan Stanley
Morgan Stanley
New York
+$7.35K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$39K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$62K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$27K +$34K +2,888 New
Morgan Stanley
3
Morgan Stanley
New York
$22K +$7.35K +625 +38%
UBS Group
4
UBS Group
Switzerland
$7K -$39K -3,317 -81%

XTLB Hedge Fund Activity: Q3 2017 in Review

4 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2017, worth a combined $118K — down 24% from $155K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $34K. The largest seller was UBS Group, cutting an estimated $39K.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2017, up from 3 in Q2 2017.
  • Funds reported $118K of XTL Biopharmaceuticals stock for Q3 2017, down 24% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q3 2017 and 0 closed out, a net change of +1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q3 2017 was Susquehanna International Group, an estimated $34K added.
  • The largest XTL Biopharmaceuticals seller in Q3 2017 was UBS Group, an estimated $39K sold.

Based on aggregated 13F filings for Q3 2017.